Robert Orlowski

MM-937: Comparative Analysis of Subcutaneous Isa VRd (ISASOCUT) and Intravenous Isa VRd (IMROZ) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Across Age Groups

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt et autres

fr, de, gr, us (code pays fourni par la source)

POSTER: CT-649: Ciltacabtagene Autoleucel Immune Effector Cell Enterocolitis Is a Clonal CAR+ Lymphoproliferative Disorder

Tania Sainz, Sharlene Dong, Aniruddha Mundhada, Wei Wang et autres

us (code pays fourni par la source)

POSTER: MM-937: Comparative Analysis of Subcutaneous Isa VRd (ISASOCUT) and Intravenous Isa VRd (IMROZ) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Across Age Groups

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt et autres

fr, de, gr, us (code pays fourni par la source)

CT-649: Ciltacabtagene Autoleucel Immune Effector Cell Enterocolitis Is a Clonal CAR+ Lymphoproliferative Disorder

Tania Sainz, Sharlene Dong, Aniruddha Mundhada, Wei Wang et autres

us (code pays fourni par la source)

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma

Minghao Dang, Robert Orlowski

us (code pays fourni par la source)

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma

Minghao Dang, Robert Orlowski

us (code pays fourni par la source)

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath C. Lionel, Lorenzo Gensini, Sherif Seif, Wenli Dong et autres

us (code pays fourni par la source)

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique M. Ocio, Aurore Perrot, Jesús F. San Miguel, Lionel Karlin et autres

es, fr, gb, it, us, gr, ca (code pays fourni par la source)

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Robert Orlowski, Mansi Shah, Rajshekhar Chakraborty, Pascual Fernández et autres

us, es, fr (code pays fourni par la source)

SACITUZUMAB TIRUMOTECAN MONOTHERAPY IN ADVANCED/METASTATIC ENDOMETRIAL CARCINOMA: RESULTS FROM A PHASE 1/2 STUDY (2870-001/KL264-01)

Xiuli Wang, Keqiang Zhang, Dong Wang, Ruifang An et autres

cn, us (code pays fourni par la source)

TIP-22. Trial in progress: A Phase Ib dose-finding study and evaluation of [177Lu]Lu-NeoB plus radiotherapy and temozolomide for newly diagnosed glioblastoma and as a single agent for recurrent glioblastoma

Patrick Y. Wen, Matthias Holdhoff, Ahmed Idbaih, Elçin Zan et autres

us, fr, ch (code pays fourni par la source)

Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone

Robert Orlowski, Meletios Α. Dimopoulos, Xavier Leleu, Meral Beksaç et autres